July 13, 2018 07:15 AM EDT
People
Financing

Bio­gen vet George Scan­gos jumps on the board at up­start MS case man­ag­er Oc­tave, backed by Sec­tion 32

John Carroll

Editor & Founder

Some promi­nent biotech ex­ecs are step­ping up to sup­port the launch of a com­pa­ny called Oc­tave Bio­science, which has been build­ing a plat­form to guide …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023

Ex­clu­sive: Bain-backed mus­cu­loskele­tal biotech rais­es $120M for trio of clin­i­cal-stage bi­o­log­ics

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times